Hindustan Unilever Limited Q3 FY2026 Results
📊
Overview
📋
Detailed Analysis
Sentiment
Mixed
Executive Summary
Hindustan Unilever Q3 FY26: Revenue ₹16,580 Cr (vs ₹15,788 Cr YoY), PAT ₹6,603 Cr (vs ₹2,989 Cr YoY)
In Q3 FY26 Hindustan Unilever reported consolidated total income of ₹16,580 Cr, up versus ₹15,788 Cr in Q3 FY25, driven by volume and price actions across categories. EBITDA for continuing operations rose to ₹3,788 Cr while EBITDA margin contracted to 23.3%, down 70 bps YoY. Profit after tax from continuing operations fell to ₹2,118 Cr from ₹3,027 Cr in Q3 FY25, but reported PAT rose to ₹6,603 Cr due to a one-off exceptional gain on the ice‑cream demerger. The Board approved acquisition of the remaining 49% of Zywie and the divestment of Nutritionalab, while management flagged a Rs.113 Cr...Total income (Consolidated, Q3 FY26)
₹16,580 Crvs ₹15,788 Cr in Q3 FY25
EBITDA (continuing ops, Q3 FY26)
₹3,788 Crvs ₹3,689 Cr in Q3 FY25
EBITDA margin (continuing ops, Q3 FY26)
23.3%vs 24.0% in Q3 FY25
Profit after tax (continuing ops, Q3 FY26)
₹2,118 Crvs ₹3,027 Cr in Q3 FY25
Reported PAT (including discontinued, Q3 FY26)
₹6,603 Crvs ₹2,989 Cr in Q3 FY25
Exceptional item – gain on demerger (Q3 FY26)
₹4,611 Crvs Nil in Q3 FY25
Basic EPS (continuing + discontinued, Q3 FY26)
₹28.12 per sharevs ₹12.70 per share in Q3 FY25
Incremental employee‑benefit liability (labour codes, as at 31 Dec 2025)
₹113 Crnot applicable
Key Highlights
10
Consolidated total income for Q3 FY26 was ₹16,580 Cr driven by continuing operations revenue growth versus ₹15,788 Cr in Q3 FY25.
EBITDA for continuing operations increased to ₹3,788 Cr in Q3 FY26 from ₹3,689 Cr in Q3 FY25, indicating operating leverage despite margin pressure.
EBITDA margin for continuing operations compressed to 23.3% in Q3 FY26, down 70 bps YoY, reflecting cost and mix pressures.
Profit after tax from continuing operations declined to ₹2,118 Cr in Q3 FY26 from ₹3,027 Cr in Q3 FY25, largely due to higher exceptional items volatility and tax effects.
Reported PAT jumped to ₹6,603 Cr in Q3 FY26 compared with ₹2,989 Cr in Q3 FY25 because of a ₹4,611 Cr exceptional gain recognised on the demerger of the Ice Cream business.
The demerger of the Ice Cream business became effective 1st December 2025 and the Group recognised the fair‑value adjustment as an exceptional gain of ₹4,611 Cr.
+4 more in Detailed Analysis →
Key Highlights
10
Consolidated total income for Q3 FY26 was ₹16,580 Cr driven by continuing operations revenue growth versus ₹15,788 Cr in Q3 FY25.
EBITDA for continuing operations increased to ₹3,788 Cr in Q3 FY26 from ₹3,689 Cr in Q3 FY25, indicating operating leverage despite margin pressure.
EBITDA margin for continuing operations compressed to 23.3% in Q3 FY26, down 70 bps YoY, reflecting cost and mix pressures.
Profit after tax from continuing operations declined to ₹2,118 Cr in Q3 FY26 from ₹3,027 Cr in Q3 FY25, largely due to higher exceptional items volatility and tax effects.
Reported PAT jumped to ₹6,603 Cr in Q3 FY26 compared with ₹2,989 Cr in Q3 FY25 because of a ₹4,611 Cr exceptional gain recognised on the demerger of the Ice Cream business.
The demerger of the Ice Cream business became effective 1st December 2025 and the Group recognised the fair‑value adjustment as an exceptional gain of ₹4,611 Cr.
Total discontinued operations result for the quarter was a profit/(loss) of ₹4,485 Cr (net presentation) reflecting demerger accounting entries for the Ice Cream undertaking.
The Group recorded a share of loss from the joint venture Nutritionalab of ₹7 Cr in Q3 FY26, as disclosed in the consolidated results.
Management noted an incremental gratuity and compensated‑absences liability of ₹113 Cr at 31 Dec 2025 due to changes in the Labour Codes, which may affect future employee cost measurement.
Board approved the acquisition of the remaining 49% of Zywie Ventures (subject to closing conditions) and approved sale/divestment of the Group's stake in Nutritionalab, with no impact on Q3 FY26 results.
Guidance & Outlook
4
Management highlighted that the demerger of the Ice Cream business is effective 1st December 2025 and will change the year‑on‑year comparability going into Q4 FY26.
Management continues to monitor the implementation of the Labour Codes and has disclosed a ₹113 Cr incremental liability as at 31 Dec 2025, signalling potential incremental employee costs ahead.
Board approval to acquire the remaining 49% of Zywie Ventures was announced on 12 Feb 2026 and is expected to proceed subject to customary closing conditions, indicating continued M&A integration focus.
The company did not provide explicit numerical FY26 revenue or margin guidance in this release, noting only that the Scheme accounting and discontinued disclosures will affect forward comparatives.
Risks & Concerns
6
EBITDA margin contraction of 70 bps YoY in Q3 FY26 signals margin pressure from cost or mix adverse movement and is a risk to near‑term operating profitability.
Profit after tax from continuing operations fell to ₹2,118 Cr in Q3 FY26 from ₹3,027 Cr in Q3 FY25, indicating underlying earnings weakness excluding the one‑off demerger gain.
The large exceptional gain of ₹4,611 Cr from the demerger materially distorts comparability and poses execution and perception risk if investors expect recurring benefits.
Incremental employee‑benefit liability of ₹113 Cr from Labour Code changes exposes the company to regulatory and cost uncertainty.
Discontinued operations accounting and demerger entries will complicate quarter‑to‑quarter comparability and may lead to volatility in reported PAT and EPS in near term.
The Group's share of loss from Nutritionalab (₹7 Cr in Q3 FY26) and the announced sale/divestment of that stake introduce execution and disposal timing risk.
AI-generated analysis. May contain inaccuracies — verify against original sources.